LABORATOIRES THEA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Efficacy, Safety of T2769 in Dry Eye Disease
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 62
- Registration Number
- NCT03830359
- Locations
- 🇹🇳
Hôpital Universitaire Tahar Sfar, Mahdia, Tunisia
🇹🇳"Hôpital Universitaire Fattouma Bourguiba, Monastir, Tunisia
🇹🇳"Hôpital de Forces de Sécurité Intérieure La Marsa, Tunis, Tunisia
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 485
- Registration Number
- NCT03825380
- Locations
- 🇪🇪
Hospital, Tallinn, Estonia
Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 11
- Registration Number
- NCT03140969
- Locations
- 🇧🇪
Ghent University Hospital and Ghent University, Ghent, Belgium
🇺🇸Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 157
- Registration Number
- NCT02979054
- Locations
- 🇹🇷
Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Turkey
🇪🇸Hospital, Vigo, Spain
🇫🇷CHU, Clermont Ferrand, France
Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 64
- Registration Number
- NCT02617095
- Locations
- 🇫🇷
Laboratoires Théa, Clermont-Ferrand, France
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 242
- Registration Number
- NCT02278614
- Locations
- 🇫🇷
Laboratoires Thea, Clermont ferrand, France
Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 609
- Registration Number
- NCT02101359
- Locations
- 🇫🇷
Laboratoires Thea, Clermont- Ferrand, France
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 105
- Registration Number
- NCT02023268
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 379
- Registration Number
- NCT02017327
- Locations
- 🇫🇷
Laboratoires Théa, Clermont ferrand, France
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 152
- Registration Number
- NCT01794312
- Locations
- 🇫🇷
Clinical Development Director, Clermont-Ferrand, France
© Copyright 2024. All Rights Reserved by MedPath